An Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients with Sickle Cell Disease

Cancer Categories

Karmanos Trial ID

NCT ID

Age Group

Scope

Phase

Principal Investigator

Pharmacokinetic Objective:

To assess the PK of orally administered Epeleuton capsules, in the treatment of patients with SCD.

Pharmacodynamic Objective:

To assess the PD and clinical activity of orally administered Epeleuton capsules, in the treatment of patients with SCD.

Safety Objective:

To assess the safety of orally administered Epeleuton capsules in the treatment of patients with SCD.

Eligibility

Inclusion Criteria:

Male or female patients aged 18 years and older on the day of signing the informed consent form (ICF)
Patients who have had between 2 and 15 episodes of vaso-occlusive crisis (VOC) in the past year (12 months)
For patients taking hydroxyurea (HU), the dose of HU must be stable for at least 3 months prior to signing the ICD and with no anticipated need for dose adjustment during the study.
Female patients and male patients with female partners of childbearing potential must use highly effective contraceptive methods for the duration of the study.

Exclusion Criteria:

Patients who are receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion), have received an RBC transfusion for any reason within three months of the baseline visit
Patients who have received a hematopoietic stem cell transplant.
Patients with inadequate venous access as determined by the Investigator

Locations

4100 John R
Detroit, MI 48201
Get Directions

Phone: 1-800-527-6266

31995 Northwestern Hwy
Farmington Hills, MI 48334
Get Directions

Phone: 1-800-527-6266

Applicable Disease Site

Therapies, Drugs, Devices